2 directors have bought £19k of Physiomics shares across 2 disclosed dealings since July 2026. 1 of those has been scored against our six-point signal check.
| 10 Jul 2026 | Ian Bagnall — Executive Director | £5,000 |
| 10 Jul 2026 | Mike Whitlow — Executive Director | £13,500 |
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.